The Wall Street Journal.Com
May 14, 2012- Updated 12:05
By: Paul Vigna
“Arena Pharmaceutical Will Be First One Out The Gate”
Lorcaserin is far safer than Qnexa (see new FoxNews video on Qnexa's poor safety) and given the fact that Qnexa's review has been delayed by three months, it seems that Lorcaserin will be first to market. With manufacturing facilities ready to go (in Switzerland) and a strong partner already signed up, we seem to be geared up to witness a blockbuster stock. Approval could launch ARNA north of $ 50 in a hurry and it stands a good chance of major blockbuster status once on the market.
I strongly recommend buying Arena Pharmaceutical ( ARNA: NASDAQ ) and again I give it a target of $15.
Close to $15, but still over 10% away.
Still keeping with $50 post approval?
Extremely doubtful now. Heck we're not is at $12.
No way we hit $50 anyway. We'll be bought out long before then. Probably at $30 by Jan.
So this person will have been wrong, not once (which is already the case) but twice.
$50 pps. lol. i WISH.